Clinical Research Studies
We do research across every area of cardiovascular care. Our research offers hope for patients, options to discuss with your doctor, and opportunities to make a difference for future patients. See the search below for a list of our active and enrolling clinical research studies and see if you may qualify to participate.
Benefits of Research
Be More Active
Take a more active role in your own health care.
Potential to Unlock More Options
You may gain access to investigational treatments and medications.
Make a Contribution
Help find a new and better way to treat people with your condition.
Search for research studies
ZEUSStudy Investigator:
Courtney Jordan Baechler, MD
About the Study:This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example, heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either receive ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment a participant receives is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Condition:
Other
|
View Study |
TREOStudy Investigator:
Xiaoyi Teng, MD
About the Study:The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. Condition:
Other
|
View Study |
SWANStudy Investigator:
Alan Bank, MD
About the Study:To understand the feasibility of characterizing walking patterns in heart failure subjects and subjects at risk for arrhythmias using an investigational wearable monitor called the SWAN study system. Condition:
Heart Failure
|
View Study |
STRIDEStudy Investigator:
Nedaa Skeik, MD
About the Study:This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for injection. Participants must inject it once a week into the stomach area, thigh, or upper arm, at any time of the day. The study will last for about 59 weeks. Participants will have 8 clinic visits and 1 phone call with the study doctor. At some clinic visits, participants will have blood tests. At some visits participants will also do a treadmill test to measure how far they can walk. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period. Condition:
Vascular Disease (Peripheral Arterial Disease)
|
View Study |
ResonanceStudy Investigator:
David Lin, MD
About the Study:The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population. Condition:
Pericarditis
|
View Study |